Merck's Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%
March 17, 2022 at 14:19 PM EDT
Merck plans to submit the data on early stage lung cancer to the FDA as soon as possible.
Photography by Christophe Tomatis